Mangafodipir (trisodium)

• UNSPSC Description:

  Mangafodipir trisodium (MnDPDP), hepatocellular-specific contrast agent, is an efficacious inhibitor of CIPN (chemotherapy-induced peripheral neuropath) and other conditions caused by cellular oxidative stress. Mangafodipir trisodium shows no negative interference with the tumoricidal activity of chemotherapy[1][2].

• Target Antigen:

  Apoptosis

• Type:

  Reference compound

• Related Pathways:

  Apoptosis

• Field of Research:

  Neurological Disease; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Mangafodipir-trisodium.html

• Purity:

  99.82

• Solubility:

  H2O : 33.33 mg/mL (ultrasonic)

• Smiles:

  O=C1[O-][Mn+2]([N]2(C3)CC4=C5COP(O)(O)=O)([O-]C6=C(N=C7)C)([O-]C4=C(N=C5)C)([O-]C3=O)[N](CC6=C7COP([O-])(O)=O)(CC2)C1.[Na+].[Na+].[Na+]

• Molecular Weight:

  757.32

• References & Citations:

  [1]Karlsson JOG, et al. Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN). Transl Oncol. 2017 Aug;10(4):641-649. |[2]Wang C. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas. Acta Radiol Suppl. 1998;415:1-31.|[3]Qin Y, et al. Protective effects of mangafodipir against chemotherapy-induced ovarian damage in mice. Reprod Biol Endocrinol. 2018 Oct 27;16(1):106.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  Launched

• CAS Number:

  140678-14-4